{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:22:43Z","timestamp":1792624963168,"version":"4.5.0"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    SA-IGIV is a human polyclonal immunoglobulin containing elevated levels of antibodies specific for the fibrinogen-binding MSCRAMM protein clumping factor A (ClfA). In vitro, SA-IGIV specifically recognized ClfA that was expressed on the surface of\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    and inhibited bacterial adherence to immobilized human fibrinogen by &gt;95%. Moreover, SA-IGIV efficiently opsonized ClfA-coated fluorescent beads and facilitated phagocytosis by human polymorphonuclear leukocytes. To determine its potential therapeutic efficacy, SA-IGIV was evaluated in combination with vancomycin in a rabbit model of catheter-induced aortic valve infective endocarditis (IE) caused by methicillin-resistant\n                    <jats:italic>S. aureus<\/jats:italic>\n                    (MRSA). The combination therapy was more effective than vancomycin alone in sterilizing all valvular vegetations when used therapeutically during early (12-h) IE. The combination therapy resulted in clearance of bacteremia that was significantly faster than that of vancomycin alone in animals with well-established (24-h) IE. Therefore, in both early and well-established MRSA IE, the addition of SA-IGIV to a standard antibiotic regimen (vancomycin) increased bacterial clearance from the bloodstream and\/or vegetations.\n                  <\/jats:p>","DOI":"10.1128\/aac.47.11.3400-3406.2003","type":"journal-article","created":{"date-parts":[[2003,10,23]],"date-time":"2003-10-23T22:33:30Z","timestamp":1066948410000},"page":"3400-3406","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":92,"title":["Anti-Clumping Factor A Immunoglobulin Reduces the Duration of Methicillin-Resistant\n                    <i>Staphylococcus aureus<\/i>\n                    Bacteremia in an Experimental Model of Infective Endocarditis"],"prefix":"10.1128","volume":"47","author":[{"given":"John","family":"Vernachio","sequence":"first","affiliation":[{"name":"Inhibitex, Inc., Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S.","family":"Bayer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Research &amp; Education Institute, Harbor-UCLA Medical Center, Torrance"},{"name":"UCLA School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuan","family":"Le","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Research &amp; Education Institute, Harbor-UCLA Medical Center, Torrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Li","family":"Chai","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Research &amp; Education Institute, Harbor-UCLA Medical Center, Torrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Prater","sequence":"additional","affiliation":[{"name":"Inhibitex, Inc., Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Schneider","sequence":"additional","affiliation":[{"name":"Inhibitex, Inc., Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Ames","sequence":"additional","affiliation":[{"name":"Inhibitex, Inc., Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Syribeys","sequence":"additional","affiliation":[{"name":"Inhibitex, Inc., Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Robbins","sequence":"additional","affiliation":[{"name":"Inhibitex, Inc., Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Patti","sequence":"additional","affiliation":[{"name":"Inhibitex, Inc., Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Bassoe C.-F. 2002. Assessment of phagocyte functions by flow cytometry p. 9.19.1-9.19.22. In J. P. Robinson Z. Darzynkiewicz P. N. Dean A. R. Hibbs A. Orfao P. S. Rabinovitch and L. L. Wheeless (ed.) Current protocols in cytometry. John Wiley & Sons Inc. New York N.Y."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1837"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.1.345-352.2001"},{"key":"e_1_3_2_5_2","unstructured":"Centers for Disease Control and Prevention. 2000. Semiannual report. Aggregated data from the National Nosocomial Infections Surveillance (NNIS) system June 2000. Centers for Disease Control and Prevention Atlanta Ga."},{"key":"e_1_3_2_6_2","first-page":"565","volume":"51","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin\u2014United States, 2002. Morb. Mortal. Wkly. Rep.51(26):565-567.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010204"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI101508"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(98)01400-0"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.7.2.314-317.2000"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00535a047"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.685"},{"key":"e_1_3_2_13_2","unstructured":"Pediatrics 1997 99"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/324430"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(96)00185-8"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19981201)33:4<406::AID-CYTO3>3.0.CO;2-L"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.5.2552-2560.1999"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1994.tb00304.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1995.tb02316.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.00416.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.2.657-664.2001"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4738-4743.1995"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1423-0410.2000.tb00061.x","volume":"78","year":"2000","unstructured":"Nydegger, U. E., P. J. Mohasci, R. Escher, and A. Morell. 2000. Clinical use of intravenous immunoglobulins. Vox Sang.78(Suppl. 2):191-195.","journal-title":"Vox Sang."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.12.6821"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.48.100194.003101"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.10.6296-6302.2001"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00535a048"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1515\/CCLM.1999.057","volume":"37","year":"1999","unstructured":"Werdan, K. 1999. Supplemental immune globulins in sepsis. Clin. Chem. Lab. Med.37:341-349.","journal-title":"Clin. Chem. Lab. Med."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Yeaman M. R. J. Lee and A. S. Bayer. 1999. Experimental Candida endocarditis p. 1709-1720. In O. Zak and M. A. Sande (ed.) Handbook of animal model infections. Academic Press New York N.Y.","DOI":"10.1016\/B978-012775390-4\/50225-6"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.11.3400-3406.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.11.3400-3406.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T23:27:01Z","timestamp":1734132421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.11.3400-3406.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1128\/AAC.47.11.3400-3406.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.11.3400-3406.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11]]},"assertion":[{"value":"2002-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-07-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}